
News|Articles|December 1, 2006
Telbivudine
Telbivudine was approved on October 25, 2006, for the treatment of chronic hepatitis B virus (HBV) in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare Part D redesign reshapes market
2
The sleep doctor who lives with a disorder he treats
3
A conversation with Tiffany Phung, Pharm.D., CSP, about how patient outcomes drive specialty pharmacy strategy
4
Rural health is ailing. Is $50 billion enough to heal it?
5













